S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,967.05 (+0.09%)
DOW   33,760.41 (-0.06%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)

Jefferies Financial Group Brokers Raise Earnings Estimates for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Rating) - Analysts at Jefferies Financial Group upped their Q4 2022 EPS estimates for shares of Calliditas Therapeutics AB (publ) in a report released on Tuesday, November 15th. Jefferies Financial Group analyst M. Raycroft now expects that the company will earn ($0.42) per share for the quarter, up from their previous estimate of ($0.57). The consensus estimate for Calliditas Therapeutics AB (publ)'s current full-year earnings is ($2.94) per share. Jefferies Financial Group also issued estimates for Calliditas Therapeutics AB (publ)'s FY2023 earnings at $3.19 EPS, FY2024 earnings at $5.98 EPS, FY2025 earnings at $8.13 EPS and FY2026 earnings at $10.74 EPS.

Separately, TheStreet lowered shares of Calliditas Therapeutics AB (publ) from a "c-" rating to a "d" rating in a research report on Tuesday, September 6th.

Calliditas Therapeutics AB (publ) Stock Down 4.2 %

Calliditas Therapeutics AB (publ) stock opened at $15.80 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 5.32 and a quick ratio of 5.32. Calliditas Therapeutics AB has a 1-year low of $10.82 and a 1-year high of $27.50. The company's 50-day moving average is $14.83 and its 200 day moving average is $16.72.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Rating) last posted its quarterly earnings data on Thursday, August 18th. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.23. Calliditas Therapeutics AB (publ) had a negative net margin of 168.20% and a negative return on equity of 71.13%. The company had revenue of $6.52 million for the quarter, compared to analyst estimates of $6.84 million.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)


Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Calliditas Therapeutics AB (publ) in the 1st quarter worth about $221,000. Tower Research Capital LLC TRC grew its stake in Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company's stock worth $51,000 after acquiring an additional 3,112 shares in the last quarter. HBK Sorce Advisory LLC bought a new position in shares of Calliditas Therapeutics AB (publ) during the third quarter valued at approximately $50,000. Optiver Holding B.V. boosted its stake in shares of Calliditas Therapeutics AB (publ) by 1,304.3% during the third quarter. Optiver Holding B.V. now owns 12,625 shares of the company's stock valued at $191,000 after purchasing an additional 11,726 shares in the last quarter. Finally, Ironwood Investment Management LLC increased its holdings in Calliditas Therapeutics AB (publ) by 5.5% during the first quarter. Ironwood Investment Management LLC now owns 28,762 shares of the company's stock valued at $551,000 after buying an additional 1,495 shares during the period. 2.94% of the stock is currently owned by institutional investors.

About Calliditas Therapeutics AB (publ)

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.

Featured Stories

Earnings History and Estimates for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Calliditas Therapeutics AB (publ) right now?

Before you consider Calliditas Therapeutics AB (publ), you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Calliditas Therapeutics AB (publ) wasn't on the list.

While Calliditas Therapeutics AB (publ) currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here